Search

Peptide

Reference library

Educational peptide reference — research use only.

Research & educational use only

For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.

The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.

KLOW

A four-peptide blend (BPC-157, GHK-Cu, TB-500, KPV) for recovery and skin research.

Half-life (approx.)
Per-component (approx.)
Diluent
Bacteriostatic water (0.9% benzyl alcohol)
Common vials
80 mg

Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.

Overview

KLOW (often labeled KLOW80) combines BPC-157, GHK-Cu, TB-500, and KPV in a four-peptide recovery and anti-inflammatory blend. The '80' designation typically refers to total milligrams — verify individual peptide fractions from analytical documentation. Four-peptide recovery stack: BPC-157 + GHK-Cu + TB-500 + KPV (KLOW80 typical total mg).

Structure & identity

Blend: BPC-157 + GHK-Cu + TB-500 + KPV (KLOW80 = 80 mg total typical)

Sequence / structure
Blend: BPC-157 + GHK-Cu + TB-500 + KPV (KLOW80 = 80 mg total typical)

Mechanism

Four-peptide recovery stack adding KPV anti-inflammatory activity to GLOW-like components. Combines repair, remodeling, and NF-κB inhibitory anti-inflammatory pathways.

Studies & clinical programs

  • Recovery + anti-inflammatory combination research

    Published research models

    • Peer-reviewed literature documents endpoints under Recovery + anti-inflammatory combination research experimental designs.

Research models in literature

  • Recovery + anti-inflammatory combination research

Literature highlights

  • Four-peptide stack adds KPV anti-inflammatory activity to GLOW-like repair components.
  • DSS colitis and skin inflammation models referenced alongside soft-tissue injury research.
  • KLOW80 denotes typical total mg — verify all four component ratios on analytical documentation.

Combination research notes

Four-way blend — calculate per-peptide dose from analytical documentation only.

Key targets & pathways

Tissue repairAnti-inflammatorySkinFour-way blend ratioAnti-inflammatory add-on

Research areas

Recovery blendAnti-inflammatoryFour-peptide mix

Routes in research literature

Subcutaneous

Also known as

KLOW80KLOWKLOW 80

Stability & storage phases

PhaseConditionGuidance
Lyophilized blendRefrigerated (2–8 °C), sealedConfirm per-peptide mg breakdown on analytical documentation before storage; blended cakes may dissolve more slowly than single-peptide vials.
ReconstitutedBacteriostatic water, refrigeratedGently swirl until all components dissolve; stability limited by the most labile peptide in the mixture — label total and per-component concentration.
Working aliquotsFrozen (−20 °C) aliquots with component ratio notedCalculate per-peptide exposure from verified blend ratios only; do not assume equal mg across components without analytical composition verification.

Stability windows are formulation-dependent — verify published data and your lab SOP.

Reconstitution reference table

Vial (mg)Diluent (mL)mcg/mLUnits @ 100 mcgUnits @ 250 mcgUnits @ 500 mcg
80326666.70.40.91.9

U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.

Reconstitution steps

  1. Confirm per-peptide composition from analytical documentation before any calculations
  2. Allow vial to reach room temperature (15–30 min)
  3. Swab stopper; inject diluent slowly down vial wall
  4. Gently swirl — blends may take longer to fully dissolve
  5. Label with date, total concentration, and component note
  6. Refrigerate; calculate per-peptide dose from verified ratios

KLOW80 denotes total mg; confirm individual component amounts before reconstitution.

Laboratory record checklist

  • Compound identity recorded in lab notebook (name, lot, preparation date)
  • Analytical identity cross-checked against published sequence or structure
  • Potency or concentration documented from analytical certificate when available
  • Purity or HPLC data filed when provided with research material
  • Appearance noted: intact lyophilized cake or uniform powder
  • Sterility / endotoxin report archived when available
  • Storage temperature applied immediately per published stability guidance